Literature DB >> 15030793

Fatty acid metabolism and vascular disease.

Clay F Semenkovich1.   

Abstract

Fatty acid metabolism is abnormal in insulin-resistant states that increase the risk of atherosclerosis such as type 2 diabetes and the metabolic syndrome. How fatty acids promote vascular disease is poorly understood, but lipoprotein lipase and peroxisome proliferator-activated receptor alpha (PPARalpha)-physiologically related proteins involved in fatty acid metabolism-may be involved. Glucocorticoid metabolism is also abnormal in insulin-resistant states and may promote several components of the metabolic syndrome. Recent studies have shown that hepatic fatty acid metabolism is required for the development of insulin resistance and hypertension caused by glucocorticoid excess, suggesting that crosstalk between glucocorticoid receptor-and PPARalpha-dependent pathways may contribute to vascular disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15030793     DOI: 10.1016/j.tcm.2003.12.004

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  13 in total

1.  Enhanced expression of adipocyte-type fatty acid binding protein in murine lymphocytes in response to dexamethasone treatment.

Authors:  Soha Abdelkawi Abdelwahab; Yuji Owada; Noriko Kitanaka; Anne Adida; Hiroyuki Sakagami; Masao Ono; Makoto Watanabe; Friedrich Spener; Hisatake Kondo
Journal:  Mol Cell Biochem       Date:  2007-05       Impact factor: 3.396

Review 2.  Heart and liver fatty acid binding proteins and the metabolic syndrome.

Authors:  Bert Binas
Journal:  Curr Hypertens Rep       Date:  2005-12       Impact factor: 5.369

Review 3.  Pathophysiology of dyslipidaemia in the metabolic syndrome.

Authors:  G D Kolovou; K K Anagnostopoulou; D V Cokkinos
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

4.  The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients.

Authors:  K Al Majali; M B Cooper; B Staels; G Luc; M-R Taskinen; D J Betteridge
Journal:  Diabetologia       Date:  2006-01-21       Impact factor: 10.122

5.  Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel.

Authors:  Kiyoshi Nakagawa; Vijaykumar R Holla; Yuan Wei; Wen-Hui Wang; Arnaldo Gatica; Shouzou Wei; Shaojun Mei; Crystal M Miller; Dae Ryong Cha; Edward Price; Roy Zent; Ambra Pozzi; Matthew D Breyer; Youfei Guan; John R Falck; Michael R Waterman; Jorge H Capdevila
Journal:  J Clin Invest       Date:  2006-05-11       Impact factor: 14.808

6.  Fatty acids regulate CREBh via transcriptional mechanisms that are dependent on proteasome activity and insulin.

Authors:  C L Gentile; D Wang; K T Pfaffenbach; R Cox; Y Wei; Michael J Pagliassotti
Journal:  Mol Cell Biochem       Date:  2010-07-04       Impact factor: 3.396

7.  Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects.

Authors:  Manoj Mathew; Eric Tay; Kenneth Cusi
Journal:  Cardiovasc Diabetol       Date:  2010-02-16       Impact factor: 9.951

8.  The role of serum monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs) in cardiovascular disease risk.

Authors:  Jasmin Kharazmi-Khorassani; Roshanak Ghafarian Zirak; Hamideh Ghazizadeh; Reza Zare-Feyzabadi; Sara Kharazmi-Khorassani; Sharzad Naji-Reihani-Garmroudi; Elham Kazemi; Habibollah Esmaily; Ali Javan-Doust; Hamed Banpour; Maryam Mohammadi-Bajgiran; Mohhamad Reza Besharatlou; Gordon A Ferns; Mohammad Hashemi; Majid Ghayour-Mobarhan
Journal:  Acta Biomed       Date:  2021-05-12

9.  Effects of NS Lactobacillus strains on lipid metabolism of rats fed a high-cholesterol diet.

Authors:  Xu Hu; Tao Wang; Wei Li; Feng Jin; Li Wang
Journal:  Lipids Health Dis       Date:  2013-05-09       Impact factor: 3.876

10.  Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.

Authors:  Vasilios G Athyros; Konstantinos Tziomalos; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Open Cardiovasc Med J       Date:  2011-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.